Pafolacianine clinical trials
Also written OTL38 and Cytalux.
How each study uses Pafolacianine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Pafolacianine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 Nov 2021 · CYTALUX · NDA 214907 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 9
On Target Laboratories, LLC (3) · University of Pennsylvania (2) · Indiana University (1) · Chandru Sundaram (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Cedars-Sinai Medical Center (1) · Mayo Clinic (1) · John Waters (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test Pafolacianine, phase 3 first.
- May 2027An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid TumorsPhase 3 · Mayo Clinic
- May 2027CYTALUX Dose Extension StudyPhase 4 · On Target Laboratories, LLC
- Aug 2027Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)Phase 4 · Cedars-Sinai Medical Center
- Nov 2027Safety and Feasibility of Intraoperative Visualization With Cytalux in ChildrenPhase 1 · Ann & Robert H Lurie Children's Hospital of Chicago
Studies
Open first, then newest update. How each study uses Pafolacianine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Safety and Feasibility of Intraoperative Visualization With Cytalux in ChildrenRecruitingPhase 1Ann & Robert H Lurie Children's Hospital of ChicagoNCT06235125Written as Cytalux
- CYTALUX Dose Extension StudyNot yet recruitingPhase 4On Target Laboratories, LLCNCT07469202Written as CYTALUX (pafolacianine) injection
- Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)RecruitingPhase 4Cedars-Sinai Medical CenterNCT07124351Written as CYTALUX™ (pafolacianine)
- An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid TumorsRecruitingPhase 3Mayo ClinicNCT06915727Written as Pafolacianine Sodium
- Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.RecruitingPhase 2John WatersNCT07039526Written as CYTALUX™ (pafolacianine) injection preoperatively
- CYTALUX™for the Intraoperative Imaging of Prostate CancerCompletedPhase 2Indiana UniversityNCT06434909Written as Cytalux™ (pafolacianine) for fluorescent imaging
- OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung NodulesCompletedPhase 2On Target Laboratories, LLCNCT02872701Written as OTL38 for Injection
- Intraoperative Imaging of Pulmonary Nodules by OTL38CompletedPhase 1University of PennsylvaniaNCT02602119Written as OTL38
- OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian CancerWithdrawnPhase 1Abramson Cancer Center at Penn MedicineNCT04941378Written as OTL38
- Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian CancerCompletedPhase 2On Target Laboratories, LLCNCT02317705Written as OTL38
- Intraoperative Folate Targeted Fluorescence in Renal Cell CarcinomaCompletedNot applicableChandru SundaramNCT02645409Written as OTL38
- Intraoperative Imaging of Pituitary Adenomas by OTLTerminatedPhase 1University of PennsylvaniaNCT02629549Written as OTL38
Given beside what is tested · 2 — Pafolacianine is usual care or a partner of the new treatment
- ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor TargetingCompletedPhase 3On Target Laboratories, LLCNCT04241315Written as OTL38 for Injection
- OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian CancerCompletedPhase 3On Target Laboratories, LLCNCT03180307Written as OTL38
As the comparator · 1 — what is tested is compared with Pafolacianine
Codes
What other systems call Pafolacianine · ClinicalTrials.gg INT001744
- MeSH (NLM) C000720187PafolacianineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) F7BD3Z4X8LPAFOLACIANINEConfirmed FDA, NLM, Wikidata
- RxNorm 2586857One source FDA
- Wikidata Q27277759pafolacianineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175834PafolacianineOne source FDA
- DrugBank DB15413One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720187 | Pafolacianine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F7BD3Z4X8L | PAFOLACIANINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2586857 | — | One source FDA |
| Wikidata | Q27277759 | pafolacianine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175834 | Pafolacianine | One source FDA |
| DrugBank | DB15413 | — | One source Wikidata |
Also registered as pafolacianine sodium (UNII 4HUF3V875C · RxNorm 2586858).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.